Individualized tacrolimus therapy: Insights from <scp>CYP3A5</scp> polymorphisms and intestinal metabolism
CYP3A4 and CYP3A5 are the most abundant and important enzymes of the CYP3A subfamily, distributed in the liver, intestinal mucosa and kidney, and involved in tacrolimus metabolism. Here, we report a case of tacrolimus dosage refractoriness due to a genetic polymorphism of <i>CYP3A5.</i>
Authors
- M Mishima (ORCID: https://orcid.org/0009-0007-0072-2870)
- Katsuhito Miyazawa (ORCID: https://orcid.org/0000-0002-0331-3753)
- Keiji Fujimoto (ORCID: https://orcid.org/0000-0003-4832-0321)
- Kengo Furuichi (ORCID: https://orcid.org/0000-0002-7069-0938)
- Yo Niida
- Ryoji Takata
- Hitoshi Yokoyama (ORCID: https://orcid.org/0000-0002-7753-1366)
- Tomohisa Yabe
- Tatsuro Tanaka
- Takaya Kondo
Institutions
- Kanazawa Medical University (JP)
- Kanazawa Medical University Hospital (JP)
Publication Details
- Journal
- Clinical Case Reports
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1002/ccr3.9416
- Citations
- 1
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.47